EPO: Proving plausibility before the EPO

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

EPO: Proving plausibility before the EPO

A common dilemma for inventors and applicants before the European Patent Office is whether an invention is sufficiently mature for a patent application to be filed. Although a proof-of-concept is often established at the date of filing, an inventor does not always have the opportunity to investigate every aspect of their invention before a patent is filed.

Typically, the EPO has been more relaxed than the USPTO or SIPO regarding this issue, and if an applicant at the EPO encounters an objection that a particular aspect of a claimed invention is not sufficiently disclosed, such an objection can typically be overcome by providing experimental evidence to the EPO that the aspect in question actually works as proposed. Experimental evidence of this nature can be post-published, i.e. the patent application can be supported by experiments carried out after the filing date.

EPO case law requires in principle that a patent claim should be examined for compliance with the requirements of sufficient disclosure (Article 83 EPC) on the basis of the application documents as originally filed. In practice, however, this requirement has not been strictly applied, and patents and patent applications often survive objections of lack of sufficiency, especially if post-published data can be provided.

Some recent decisions of the EPO Boards of Appeal in the pharmaceutical field have developed the existing case law around how plausible the technical effect of an invention must be at the filing date of the patent application.

In decisions T 0488/16 (Dasatinib I) and T 0950/13 (Dasatinib II), the Board required that the technical problem underlying the invention was at least plausibly solved at the filing date. This required technical evidence if the effect is "neither self-evident nor predictable or based on a conclusive theoretical concept". Post-filed evidence and declarations by experts that the products did in fact work as envisaged were not sufficient, and the patents were deemed to lack inventive step.

Decision T 2500/12 (Alzheimer) concerned an immunogen for a pharmaceutical composition in the accepted second-medical use form (for use in the treatment, prevention or amelioration in an animal of Alzheimer's disease or other diseases characterised by amyloid deposits). The Board was not convinced that the suitability of the immunogen claimed for the particular treatment was shown in the application as filed, or in the prior art. The patent claim was found to be insufficiently disclosed.

If these decisions form part of a trend, obtaining valid patent claims on the more speculative aspects of an invention may prove to be more difficult before the EPO.

Edward J Farrington

Inspicos A/S

Kogle Allé 2

DK-2970 Hoersholm

Copenhagen, Denmark

Tel: +45 7070 2422

Fax: +45 7070 2423

info@inspicos.com

www.inspicos.com

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article